Published in Vaccine Weekly, December 14th, 2005
The new contracts add to CBI's expanding contract base in biodefense and vaccine development support activities. Coming on the heels of a record revenue quarter for CBI and one in which $1.5 million in new contract work was announced recently, these new contracts are more evidence of CBI's growing market share in these two key growth areas. Work on both contracts has already begun and will continue throughout 2006 and into 2007. Revenues from these new contracts are expected to be realized in the fourth...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.